BCL2L11 and Splenomegaly: Bcl2l11−/−Faslpr/lpr and even Bcl2l11+/−Faslpr/lpr mice developed lymphadenopathy and splenomegaly at a dramatically increased magnitude and rate compared to mice lacking either apoptosis initiator alone (Figure 4; Figure S5).